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Antimicrobial susceptibility, inducible
macrolide-lincosamide-streptogramin B,
and clonal diversity patterns of nosocomial
methicillin-resistant Staphylococcus aureus strains
isolated in Hacettepe University adult hospital
Aim: Nosocomial infections due to methicillin resistant Staphylococcus aureus (MRSA) are an
important problem with limited therapeutic options. The aim of this study was to determine the
vancomycin, teicoplanin, linezolid, tigecycline, erythromycin, gentamicin, ciprofloxacin, rifampin,
trimethoprim/sulfamethoxazole, and clindamycin susceptibility, inducible macrolide-lincosamidestreptogramin B (iMLSB) resistance, and clonal diversity patterns of 109 mecA positive Staphylococcus
aureus strains isolated from patients with nosocomial infections in Hacettepe University Adult
Hospital between 2002 and 2004.
Materials and methods: The nosocomial isolates of S. aureus from various clinical samples (58 blood,
45 pus, 6 catheter) were identified by Sceptor (Becton Dickinson, USA) automated system.
Polymerase chain reaction (PCR) was performed for the presence of mecA gene of the MRSA isolates.
The susceptibility to vancomycin, teicoplanin, linezolid, and tigecycline was determined by Etest
(AB Biodisk, Sweden) and to the other antibiotics by disk diffusion methods according to the CLSI
recommendations. Inducible macrolide-lincosamide-streptogramin B (iMLSB) resistance phenotypes
were determined by the double disk method. Pulse field gel electrophoresis (PFGE) was performed
to examine the clonal diversity.
Results: All MRSA strains were susceptible to vancomycin, teicoplanin, linezolid, and tigecycline
with MIC90 (μg/mL) values of 2, 2, 2, and 0.25, respectively. The isolates were highly resistant (≥90%)
to
gentamicin,
ciprofloxacin,
and
rifampin,
whereas
the
susceptibility
to
trimethoprim/sulfamethoxazole was 89%, to clindamycin was 62%, and to erythromycin was 46%.
IMLSB resistance was determined among 13% of the MRSA strains. Thirteen different clones were
shown by PFGE, whereas 80% of the isolates were in a dominant clone.
Conclusion: Vancomycin, teicoplanin, linezolid, and tigecycline were highly active against
nosocomial isolates of MRSA in our hospital. Although these are effective therapeutic options for
MRSA, the high rate of cross-contamination of the patients is a matter of concern. We should pay
more attention to infection control practices.
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Hacettepe Üniversitesi erişkin hastanesi’nde izole edilen hastane
enfeksiyonu etkeni metisiline dirençli Staphylococcus aureus
suşlarının antimikrobiyallere duyarlılık, indüklenebilir
makrolid-linkozamid-streptogramin B direnç ve
klonal benzerlik durumları
Amaç: Metisiline dirençli Staphylococcus aureus (MRSA)’a bağlı gelişen nozokomiyal enfeksiyonlar
tedavide az sayıda seçenek olması nedeniyle önemli bir sorun oluşturmaktadır. Bu çalışmada
Hacettepe Üniversitesi Erişkin Hastanesi’nde 2002-2004 yılları arasında hastane enfeksiyonu etkeni
olarak izole edilen mecA geni pozitif 109 Staphylococcus aureus suşunun vankomisin, teikoplanin,
linezolid, tigesiklin, eritromisin, gentamisin, siprofloksasin, rifampin, trimethoprim-sulfametoksazol
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ve klindamisine karşı duyarlılık, indüklenebilir makrolid-linkozamid-streptogramin B (iMLSB) direnç
ve klonal benzerlik durumlarının belirlenmesi amaçlanmıştır.
Yöntem ve gereçler: Farklı klinik örneklerden (58 kan, 45 püy, 6 kateter) izole edilen S. aureus
suşlarının tür düzeyindeki tanımlaması Sceptor (Becton Dickinson, ABD) otomatize sistemi ile
yapılmıştır. Otomatize sistemden metisiline dirençli S. aureus (MRSA) olarak rapor edilen izolatların
mecA geni varlığı PZR yöntemiyle gösterilmiştir. Vankomisin, teikoplanin, linezolid ve tigesiklin için
duyarlılık testleri Etest (AB Biodisk, İsveç) ile üretici firma önerilerine uygun olarak
gerçekleştirilmiştir. Diğer antibiyotiklere karşı duyarlılık disk difüzyon yöntemi ile belirlenip, sonuçlar
CLSI kriterlerine göre yorumlanmıştır. İMLSB direnci çift disk difüzyon, suşlar arasındaki klonal
benzerlik ‘pulse field gel electrophoresis (PFGE)’ yöntemi ile belirlenmiştir.
Bulgular: MRSA izolatlarının vankomisin, teikoplanin, linezolid ve tigesiklin MİK90 değerleri
sırasıyla 2, 2, 2 ve 0,25 μg/ml ve tümü bu antibiyotiklere duyarlı olarak saptanmıştır. Bununla birlikte
tüm izolatlar gentamisin, siprofloksasin ve rifampisine yüksek oranda (≥% 90) dirençli; trimetoprim/
sülfametaksazole % 89, klindamisine % 62 ve eritromisine % 46 oranında duyarlı bulunmuştur.
MRSA izolatlarının % 13’ünde iMLSB direnci saptanmıştır. PFGE analizi sonucunda 13 farklı klon
saptanmış, izolatların % 80’inin belli bir tek klonda yer aldığı gözlenmiştir.
Sonuç: Vankomisin, teikoplanin, linezolid ve tigesiklin hastanemizde izole edilen MRSA suşlarına
karşı yüksek düzeyde aktivite göstermektedir. MRSA enfeksiyonlarının tedavisi için etkin
seçeneklerimiz olmasına rağmen, klonal analiz sonuçlarına göre hastalar arasında yüksek oranda
çapraz bulaş saptanması endişe uyandırmaktadır. Bu durum enfeksiyon kontrol önlemlerine daha
fazla dikkat göstermemiz gerektiğini göstermektedir.
Anahtar sözcükler: Metisiline Dirençli Staphylococcus aureus (MRSA), antibiyotiklere duyarlılık,
makrolid-linkozamid-streptogramin direnci (iMLSB), pulse field gel electrophoresis (PFGE)

Introduction
Methicillin-resistant Staphylococcus aureus
(MRSA) is one of the most important causes of
nosocomial infections worldwide. It is known to be
encoded by the mecA gene and is mostly multiresistant to a wide range of antibiotics (1).
The glycopeptides vancomycin, teicoplanin and an
oxazolidinone linezolid have been regarded as the
drug of choice for the treatment of MRSA infections
(2). However, vancomycin-intermediate (VISA) and
-resistant isolates of S. aureus (VRSA) have been
described in some countries (3). Recently, tigecycline
represents an exciting new class of glycylcycline
antimicrobial agents for the treatment of multi-drug
resistant gram-positive bacteria (4).
This study was conducted to determine the
vancomycin, teicoplanin, linezolid, tigecycline, as well
as erythromycin, gentamicin, ciprofloxacin, rifampin,
trimethoprim/sulfamethoxazole, and clindamycin
susceptibility, inducible macrolide-lincosamidestreptogramin B (iMLSB) resistance, and clonal
diversity patterns of mecA positive S. aureus strains
isolated from patients with nosocomial infections in
784

Hacettepe University Adult Hospital between 2002
and 2004.
Methods
Strains
All MRSA isolates from clinical samples of
inpatients with nosocomial infections at Hacettepe
University Adult Hospital between 2002 and 2004
were included in the study. Only one isolate from each
patient was included in the study. The identification of
the isolates was made by Sceptor automated system
(Becton Dickinson, USA) and methicillin resistance
was confirmed by the presence of the mecA gene by
polymerase chain reaction (PCR), which is considered
the ‘gold standard’ in the determination of
heterogeneous resistance. Pulse field gel
electrophoresis (PFGE), which is the ‘gold standard’
as a genotypic typing method, was performed to
examine the clonal diversity. The isolates were stored
at -80 °C until studied. S. aureus ATCC 29213, S.
aureus 27R, and S. aureus 8328 were included as
control strains.

Vol: 39

No: 5

Antimicrobial susceptibility of MRSA

Antibiotic susceptibility tests
Susceptibility testing against erythromycin (15 μg),
gentamicin (10 μg), ciprofloxacin (5 μg), rifampin (5
μg), trimethoprim/sulfamethoxazole (TMP-SMX,
1.25/23.75 μg), and clindamycin (2 μg) disks (Oxoid,
UK) was performed on Mueller Hinton agar (MHA)
(Oxoid, UK) incubated at 35 °C for 12-16 h. In
addition, Etest strips (AB Biodisk, Sweden) were used
to test the susceptibility against vancomycin,
teicoplanin, linezolid, and tigecycline with an
inoculum of McFarland 2.0 onto brain heart infusion
agar (BHIA) (Oxoid, UK) according to the
manufacturer’s recommendations. The results were
interpreted according to CLSI criteria (5). Moreover,
inducible and constitutive macrolide-lincosamidestreptogramin B (iMLSB) resistance phenotypes were
determined by double disk method with
erythromycin and clindamycin disks placed at a
distance of 15-20 mm. After 18 h of incubation at 37
°C, blunting of the clindamycin zone of inhibition
near the erythromycin disk indicated iMLSB resistance
and resistance to both erythromycin and clindamycin
indicated constitutive MLSB resistance (6). For
tigecycline, interpretive criteria from the US Food and
Drug Administration packaging insert were applied
as susceptible ≤0.5 μg/mL (7).
PCR
The isolation of bacterial DNA was performed as
described previously (8). Amplification was
performed in a mixture consisting of 50 mM Tris (pH
8.3), 50 mM KCl, 2.5 mM MgCl2, 0.2 mM of
deoxyribonucleotide triphosphates (dATP, dGTP,
dCTP, and dTTP), 50 pmol of each primer, 0.5 U Taq
DNA Polymerase (MBI Fermentas, USA), and 5 mL
of staphylococcal DNA extract. The sequences of the
primers mecA1 and mecA2 were 5’ GTT GTA GTTB
GTC GGG TTT GG 3’ and 5’ CCA CCC AAT TTG
TCT GCC AGT TTC 3’, respectively. The
amplification was performed in a Flexigene (Techne,
Cambridge, UK) thermalcycler by a program
consisting of an initial denaturation step at 94 °C for
4 min; this was followed by 30 cycles of 94 °C for 30 s,
55 °C 30 s, 72 °C 2 min, and 72 °C for 5 min (9). PCR
products were then separated by electrophoresis in
1.5% agarose gels with 1× Tris-acetate EDTA (TAE)
running buffer (40 mM Tris-acetate, 1 mM EDTA)
and visualized on a UV transilluminator and
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photographed. The molecular weight standard was
φx174 (MBI Fermentas, USA). Isolates with the mecA
genotype showed a 1817 bp band.
PFGE
MRSA DNA embedded in agarose blocks was
prepared as described by Lencastre (10). The DNA
fixed in the agarose disk was incubated for 20 h in 45
μL of restriction buffer and Sma I (20 U). The reaction
was stopped with 5 μL of loading buffer. Gels with
1.1% agarose (Genexis Spech bach, Germany) were
prepared in 0.5 × TBE buffer (50 mM boric acid, 0.2
mM EDTA). PFGE was carried out by General
Navigator, Pharmacia (Uppsala, Sweden). The
running conditions were performed for 22 h at 14 °C
at 150 V. Pulse times were 20 s for 15 h, 35 s for 7 h,
50 s for 15 h, and 90 s for the last 3 h.
Results
A total of 109 MRSA isolates from different
clinical samples (58 blood, 45 pus, 6 catheter) were
included in the study. The methicillin resistance of all
S. aureus isolates included in the study was confirmed
by detection of the mecA gene. All isolates were multidrug resistant (≥3 groups of antibiotics). They were
highly resistant (≥90%) to the antimicrobials
gentamicin, ciprofloxacin, and rifampin, whereas the
susceptibility to TMP-SMX was 89%, to clindamycin
was 62%, and to erythromycin was 46%. Of the 68
clindamycin-susceptible strains, 14 had iMLSB
resistance. Overall 13% of the isolates had iMLSB
resistance. All MRSA strains were susceptible to
vancomycin, teicoplanin, linezolid, and tigecycline
with MIC90 (μg/mL) values of 2, 2, 2, and 0.25
respectively (Table).
PFGE analysis of genomic DNA from 109 isolates
revealed 13 different clones (Figure). One epidemic
clone (clone A) was identified for 87 isolates (79.8%).
Six other clones contained 5, 3, 2, 2, 2, and 2 isolates,
respectively. There were also 6 different sporadic
clones each contained a single isolate.
Discussion
MRSA is one of the leading causes of nosocomial
infections worldwide. In a multicenter study, the
prevalence of MRSA infections was reported to be
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Table.

Antimicrobial resistance of 109 nosocomial MRSA
strains isolated in Hacettepe University Adult Hospital
between 2002 and 2004.

Antimicrobial agent

infected with MRSA. Alcohol-based hand rinses are
available at the bedsides of patients infected with
MRSA in wards and regardless of infection with
MRSA at the ICU. Since MRSA colonization often
precedes infection there is great interest in
decolonizing persons who harbor these bacteria. The
most extensive research in MRSA decolonization has
been conducted with mupirocin, which is applied to
the anterior nares 2-3 times/day for 5 days. Routine
decolonization is not prudent unless MRSA
colonization is confirmed in the nares or other site.
Screening for MRSA colonization is not a routine
infection control practice in our hospital and we do
not use mupirocin for decolonization. The
compliance to infection control practices such as hand
hygiene and isolation precautions is poor in our
hospital, mainly due to the overcrowding of patients
and the inadequate number of medical staff.

Resistance (%)

Clindamycin
Erythromycin
TMP-SXT
Rifampin
Gentamicin
Ciprofloxacin
Vancomycin
Teicoplanin
Linezolid
Tigecycline

38*
54
11
90
93
95
-

* Although 62% of the strains were susceptible to clindamycin,
13% had iMLSB resistance

>40% in southern and western European hospitals
(11). The prevalence of methicillin resistance among
nosocomial S. aureus isolates was 70% in Hacettepe
University Adult Hospital between 2000 and 2004 (12,
Unpublished data). According to PFGE analysis, a
dominant clone was prevalent in our hospital, which
is a serious concern for an effective infection control
program. Contact isolation is performed for patients
infected with MRSA in our hospital. All intensive care
units are visited daily by an infection control nurse.
There are reminder posters about the infection
control measures on the walls and cautionary cards
are placed at the bedsides of the patients who are
A

L

E

N

F

A

K

C

G
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The high rates of resistance to ciprofloxacin,
rifampin, and gentamicin were significant. Similar
results had been reported from a different center in
Turkey, recently (13). The susceptibility rate of MRSA
strains to TMP-SMX is 89% in this study. Moreover,
Samra et al. reported the TMP-SMX susceptibility of
nosocomial MRSA strains as 86% (14).
Although 62% of the strains were susceptible to
clindamycin, the high rate of erythromycin resistance
raised the question of inducible resistance and iMLSB
resistance was determined in 13% of MRSA isolates.
Different resistance rates have been reported from
D

H

M

A

B

O

O

A

A NCTC

Figure. PFGE analysis of different clonal patterns of MRSA isolates.
Lanes 1, 6, 13, 17, 18 pattern A, lane 2 pattern L, lane 3 pattern E, lane 4 pattern
N, lane 5 pattern F, lane 7 pattern K, lane 8 pattern C, lane 9 pattern G, lane 10
pattern D, lane 11 pattern H, lane 12 pattern M, lane 16 pattern B, lanes 15, 16
pattern O, lane 19 NCTC isolate.
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different geographical regions for iMLSB resistance.
Delialioglu et al. reported 5.4% inducible phenotype
among 128 MRSA strains from Turkey (15). Inducible
clindamycin resistance has been reported in 5.6% of
108 MRSA isolates from Başkent University Hospital,
Turkey (16). However, in a study from Maryland,
USA, that examined 161 clinical MRSA isolates for
iMLSB resistance, 56% of the strains harbored iMLSB
resistance (17), and similar high rates were also
reported from India (18). These results clearly
indicate that, based on institution and geographic
region, the prevalence rates of iMLSB phenotypes vary.
The reason for this is not clear and it is a good subject
for further research. Vancomycin, teicoplanin,
linezolid, and tigecycline had very good activity
against MRSA isolates in this study. Glycopeptides are
recommended therapeutic options for MRSA
infections, but acquired resistance to vancomycin in
staphylococci has become known in recent years and
many clinicians are concerned about the significance
of acquired resistance that could show a rapid
progress in clinical use (19-24). Furthermore,
teicoplanin resistant S. aureus has been reported from
the Mediterranean region (25,26). There has been no
VRSA report in Turkey, but there was a report of
VISA strains isolated from various clinical samples in
2005 (27). Amongst 256 MRSA isolates 46 had
reduced susceptibility to vancomycin. Twelve of the
46 patients with hetero-VISA had a history of
previously treatment with vancomycin or teicoplanin.
In another study, 1 (1.2%) out of 81 S. aureus isolates
had intermediate resistance to teicoplanin (MIC 16
mg/L), but VISA was not detected. Six strains of
Staphylococcus haemolyticus (13%) out of 54
coagulase negative staphylococci (CoNS) were
detected to have heterogeneously reducing
susceptibility to vancomycin (MICs ranged between
5 and 8 mg/L) (28). In this study we did not examine
the heterogeneous resistance to glycopeptides. Besides
resistance, the vancomycin MIC may have important
consequences on the efficacy of this antibiotic and on
mortality in patients with bacteremia due to MRSA.
Mortality associated with MRSA bacteremia was
significantly higher when vancomycin was
empirically used for treatment of infection with
strains with a high vancomycin MIC (>1 mg/mL)
(29).

October 2009

Gram-positive cocci are rarely resistant to
linezolid. A recent study examined the linezolid
susceptibility of 1930 isolates of MRSA collected from
the different regions of the United States; 99.9% were
susceptible to linezolid (30). Two clinical isolates of
MRSA resistant to linezolid have been reported from
different parts of the world (31,32). There are 2 other
reports about linezolid susceptibility of MRSA strains
in Turkey. The first study includes 127 MRSA strains
and the second includes 38, and all are susceptible to
linezolid (33,34). Clinical outcomes are significantly
better with linezolid than with vancomycin in several
indications (35,36). The efficacy and safety of
linezolid and vancomycin were compared for the
treatment of nosocomial pneumonia, complicated
skin and soft-tissue infections, or sepsis caused by
MRSA infections in Japan, recently. One hundred
patients received linezolid and 51 received
vancomycin with outcomes evaluated at the end of
therapy (EOT). At EOT, clinical success rates in the
MRSA microbiologically evaluable population were
62.9% and 50.0% for the linezolid and vancomycin
groups, respectively; and microbiological eradication
rates were 79.0% and 30.0% in the 2 groups,
respectively (P ≤ 0.0001). Reversible anemia (13%)
and thrombocytopenia (19%) were reported more
frequently in linezolid patients (37).
Tigecycline, a new glycylcycline antibiotic, has
shown promising in vitro activity against many
common pathogens, including MRSA. The MIC90 of
tigecycline against S. aureus was 0.25 μg/mL in a study
performed at 40 study centers in 11 countries (38).
Tigecycline was shown to be non-inferior to
combination vancomycin-aztreonam regimens and
exhibited high clinical success rates for complicated
soft tissue infections. MIC90 values for tigecycline
were uniformly low for both susceptible and resistant
pathogens. Adverse events were similar in incidence
for both patient populations, with nausea and
vomiting reported more frequently with tigecycline
treated patients while rash and elevated liver
transaminases were most commonly observed in the
vancomycin-aztreonam treatment group (39). A
randomized (3:1), double-blind, multicentre, phase 3
study compared the safety and efficacy of tigecycline
with vancomycin in hospitalized patients with MRSA.
787
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Clinical cure rates in the microbiologically evaluable
population (n = 117) were 81.4% (70 of 86 patients)
with tigecycline and 83.9% (26 of 31 patients) with
vancomycin (40).
In conclusion, glycopeptides and linezolid are
effective drugs for MRSA infections in our hospital.

Turk J Med Sci

Moreover, tigecycline is a promising alternative for the
treatment of MRSA infections. Even though there are
effective therapeutic options, surveillance of
resistance should guide the selection of empirical
therapy and continuous attention should be paid to
infection control measures.
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